Daily CSR
Daily CSR

Daily CSR

Daily news about corporate social responsibility, ethics and sustainability
Tags (5) : drug development

Syngene Extends Strategic Partnership with Bristol Myers Squibb Through 2035

Syngene Extends Strategic Partnership with Bristol Myers Squibb Through 2035
01/21/2026 | Companies
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced the renewal and extension of its long-term strategic partnership with Bristol Myers Squibb through 2035. The enhanced agreement significantly expands the range of integrated...
biopharmaceutical industry, Bristol Myers Squibb, cardiovascular research, clinical biomarkers, clinical trials, contract research organization, CRDMO, drug development, drug discovery, drug metabolism and pharmacokinetics, end-to-end solutions, fibrosis research, global pharma, immunology research, innovation in healthcare, integrated services, life sciences, manufacturing excellence, oncology research, patient-centric research, pharmaceutical development, pharmaceutical manufacturing, preclinical development, R&D partnership, research collaboration, strategic partnership, Syngene International, translational sciences

Ribo Life Science Lists on HKEX, Raising HKD 1.8 Billion in siRNA IPO

Ribo Life Science Lists on HKEX, Raising HKD 1.8 Billion in siRNA IPO
01/09/2026 | Companies
Ribo Life Science Co., Ltd, a pioneer in the development of small interfering RNA (siRNA) therapies, has successfully debuted on the Main Board of the Hong Kong Stock Exchange. This achievement represents an important step forward for the capitalization of China’s biopharmaceutical sector in the...
biopharmaceutical industry, biotechnology innovation, capital markets, Chinese biotech, clinical trials, cornerstone investors, drug development, global offering, healthcare innovation, HKEX IPO, Hong Kong Stock Exchange, investor confidence, liver-targeted delivery, research and development, Ribo Life Science, RiboGalSTAR, RNA interference, siRNA therapeutics

Gilead Sciences Leads in Innovation & Responsibility

Gilead Sciences Leads in Innovation & Responsibility
03/20/2025 | Companies
We’re honored to once again be recognized among the top five most just companies in the biopharmaceutical industry in the United States. This recognition highlights our continued dedication to responsible business practices and empowering our workforce to contribute to a healthier global community....
biopharmaceuticals, corporate responsibility, drug development, employee empowerment, Foster City California, Gilead Sciences, global health, global operations, healthcare, innovative medicines, life-threatening illnesses, medical innovation, medical research, responsible business, top biopharma companies

Enhancing Diversity in Clinical Trials: Why It Matters for Drug Development

Enhancing Diversity in Clinical Trials: Why It Matters for Drug Development
01/15/2025 | Companies
Clinical trials play a vital role in the development of healthcare products, and there is an increasing awareness of the need for more diversity in participant pools. With the recent introduction of draft guidelines by the US Food and Drug Administration (FDA) that make Diversity Action Plans...
clinical research, clinical trial barriers, clinical trial diversity, clinical trial inclusion, clinical trial participation, clinical trial statistics, clinical trials, cultural competency, diversity in clinical trials, drug development, ethnic diversity, FDA guidelines, health equity, healthcare access, healthcare disparities, healthcare diversity, medical research, patient-centered development, pharmaceutical industry, Teva, underrepresented groups

Brii Biosciences Acquires Full Rights to BRII-179 for HBV Cure Advancement

Brii Biosciences Acquires Full Rights to BRII-179 for HBV Cure Advancement
01/01/2025 | Companies
Brii Biosciences Limited, a biotechnology company focused on developing treatments for diseases with significant unmet needs, announced its acquisition of intellectual property (IP) and other assets related to BRII-179 from VBI Vaccines, Inc., its subsidiaries, and creditors K2 VBI Equity Trust,...
biotechnology, Brii Biosciences, BRII-179, clinical trials, combination therapies, drug development, elebsiran, ENRICH study, functional cure, HBV, healthcare innovation, Hepatitis B Virus, intellectual property acquisition, know-how, patents, PEG-IFNα, Phase 2b study, shareholder value, unmet medical needs, VBI Vaccines


Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com